Vasculitis Overview

The term “vasculitis” refers to a set of uncommon disorders that cause blood vessel inflammation. Veins and arteries are among these vessels. Vasculitis comes in a variety of forms, each with its own set of symptoms, degree of severity, and time course. Vasculitis comes in a variety of unusual forms, and the causes are mostly unknown.

“Vasculitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vasculitis Market.

The Vasculitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Vasculitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Vasculitis treatment therapies with a considerable amount of success over the years. Vasculitis Key players such as – Ambulero, Ambulero, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, and others, are developing therapies for the Vasculitis treatment 

• Vasculitis Emerging therapies such as – AMB 301, Visterra, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, and others are expected to have a significant impact on the Vasculitis market in the coming years.   
• In October 2021, Novartis Pharmaceuticals initiated a Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Route of Administration

Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

• Bispecific Antibody
• Peptides 
• Small molecule
• Gene therapy

Vasculitis Pipeline Therapeutics Assessment

• Vasculitis Assessment by Product Type
• Vasculitis By Stage and Product Type
• Vasculitis Assessment by Route of Administration
• Vasculitis By Stage and Route of Administration
• Vasculitis Assessment by Molecule Type
• Vasculitis by Stage and Molecule Type

DelveInsight’s Vasculitis Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Vasculitis Therapeutics Market include:

Key companies developing therapies for Vasculitis are – CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics,  Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and many others.

Emerging Vasculitis Drugs Under Different Phases of Clinical Development Include:

• Belimumab: GlaxoSmithKline
• AMB 301: Ambulero
• Research programme: kideny disorder therapeutics : Visterra
• BDB 1: Beijing Defengrei Biotechnology
• Vilobelimab: InflaRx
• Guselkumab: Janssen Biotech
• Secukinumab: Novartis
• Upadacitinib: AbbVie

Get a Free Sample PDF Report to know more about Vasculitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight

Vasculitis Pipeline Analysis:

The Vasculitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Vasculitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vasculitis Treatment.
• Vasculitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vasculitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Vasculitis product details are provided in the report. Download the Vasculitis pipeline report to learn more about the emerging Vasculitis therapies

Vasculitis Pipeline Market Drivers

• Rising incidence of Vasculitis
• The surge in R&D on the treatment of Vasculitis
• Technological advancement in the diagnostic kits

Vasculitis Pipeline Market Barriers

• Side effects caused by the current treatment methods
• Lack of trained professionals and stringent governmental regulations for Vasculitis drugs

Scope of Vasculitis Pipeline Drug Insight    

• Coverage: Global
• Key Vasculitis Companies: Ambulero, Ambulero, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, and others
• Key Vasculitis Therapies: AMB 301, Visterra, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, and others
• Vasculitis Therapeutic Assessment: Vasculitis current marketed and Vasculitis emerging therapies
• Vasculitis Market Dynamics: Vasculitis market drivers and Vasculitis market barriers 

Request for Sample PDF Report for Vasculitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Vasculitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting